UbiVac

UbiVac is a clinical-stage biotechnology company dedicated to the research and development of therapeutic vaccines for cancer treatment. UbiVac was spun off in 2005 from the Robert W. Franz Cancer Research Center at Providence Portland Medical Center in Portland, Oregon, where it continues to build on groundbreaking immunotherapy research and is preparing to launch new combination immunotherapy clinical trials. These trials, targeting advanced triple-negative breast cancer (TNBC) and advanced head and neck squamous cell carcinoma (HNSCC), are expected to commence in mid-2020, combining UbiVac's first-in-class DPV vaccine technology with immune enhancers and checkpoint blockade.